Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleHot Topics

FAP: The Next Billion Dollar Nuclear Theranostics Target?

Jeremie Calais
Journal of Nuclear Medicine February 2020, 61 (2) 163-165; DOI: https://doi.org/10.2967/jnumed.119.241232
Jeremie Calais
1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California
2Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California
3Physics & Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California; and
4Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 61 no. 2 163-165
DOI 
https://doi.org/10.2967/jnumed.119.241232
PubMed 
31924719

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication December 19, 2019
  • Accepted for publication January 8, 2020
  • Published online February 3, 2020.

Article Versions

  • previous version (January 10, 2020 - 04:59).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

Statistics from Altmetric.com

Cited By...

  • 74 Citations
  • 80 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy
    Dirk Zboralski, Aileen Hoehne, Anne Bredenbeck, Anne Schumann, Minh Nguyen, Eberhard Schneider, Jan Ungewiss, Matthias Paschke, Christian Haase, Jan L. von Hacht, Tanya Kwan, Kevin K. Lin, Jan Lenore, Thomas C. Harding, Jim Xiao, Andrew D. Simmons, Ajay-Mohan Mohan, Nicola Beindorff, Ulrich Reineke, Christiane Smerling, Frank Osterkamp
    European Journal of Nuclear Medicine and Molecular Imaging 2022 49 11
  • State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis
    Martina Sollini, Margarita Kirienko, Fabrizia Gelardi, Francesco Fiz, Noemi Gozzi, Arturo Chiti
    European Journal of Nuclear Medicine and Molecular Imaging 2021 48 13
  • An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications
    Jacopo Millul, Gabriele Bassi, Jacqueline Mock, Abdullah Elsayed, Christian Pellegrino, Aureliano Zana, Sheila Dakhel Plaza, Lisa Nadal, Andreas Gloger, Eleonore Schmidt, Ilaria Biancofiore, Etienne J. Donckele, Florent Samain, Dario Neri, Samuele Cazzamalli
    Proceedings of the National Academy of Sciences 2021 118 16
  • Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
    Mengxin Xu, Pu Zhang, Jie Ding, Junyi Chen, Li Huo, Zhibo Liu
    Journal of Nuclear Medicine 2022 63 6
  • [68 Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity
    Zachary T. Rosenkrans, Christopher F. Massey, Ksenija Bernau, Carolina A. Ferreira, Justin J. Jeffery, Jefree J. Schulte, Melissa Moore, Frank Valla, Jeanine M. Batterton, Christopher R. Drake, Alan B. McMillan, Nathan Sandbo, Ali Pirasteh, Reinier Hernandez
    European Journal of Nuclear Medicine and Molecular Imaging 2022 49 11
  • 18F-labeled tracers targeting fibroblast activation protein
    Thomas Lindner, Annette Altmann, Frederik Giesel, Clemens Kratochwil, Christian Kleist, Susanne Krämer, Walter Mier, Jens Cardinale, Hans-Ulrich Kauczor, Dirk Jäger, Jürgen Debus, Uwe Haberkorn
    EJNMMI Radiopharmacy and Chemistry 2021 6 1
  • Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging
    Agathe Peltier, Romain-David Seban, Irène Buvat, François-Clément Bidard, Fatima Mechta-Grigoriou
    Seminars in Cancer Biology 2022 86
  • Non-oncologic incidental uptake on FAPI PET/CT imaging
    Masatoshi Hotta, Angela C Rieger, Mahbod G Jafarvand, Nandakumar Menon, Andrea Farolfi, Matthias R Benz, Jeremie Calais
    The British Journal of Radiology 2023 96 1142
  • FAPI PET/CT Imaging—An Updated Review
    Kunal Ramesh Chandekar, Arun Prashanth, Sobhan Vinjamuri, Rakesh Kumar
    Diagnostics 2023 13 12
  • Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography
    Hallie M. Hintz, Joseph P. Gallant, Donald J. Vander Griend, Ilsa M. Coleman, Peter S. Nelson, Aaron M. LeBeau
    Clinical Cancer Research 2020 26 18

Article usage

Article usage: January 2020 to April 2025

AbstractFullPdf
Jan 2020180183
Feb 2020161310659
Mar 20200194174
Apr 2020014392
May 2020012379
Jun 202009175
Jul 2020011061
Aug 202009464
Sep 20200111100
Oct 202008384
Nov 202007282
Dec 2020012279
Jan 2021011956
Feb 2021017281
Mar 20210295161
Apr 20210282544
May 20210269173
Jun 20210340147
Jul 2021030195
Aug 20210183112
Sep 2021021283
Oct 2021020891
Nov 20210175113
Dec 2021013448
Jan 2022014996
Feb 20220221122
Mar 2022015474
Apr 2022014188
May 20220185114
Jun 2022013371
Jul 2022014973
Aug 2022017182
Sep 2022013577
Oct 202209159
Nov 2022016578
Dec 20220137107
Jan 2023014457
Feb 2023012062
Mar 2023021776
Apr 2023014183
May 2023014575
Jun 2023015390
Jul 2023014960
Aug 2023021460
Sep 2023020654
Oct 2023043873
Nov 2023047061
Dec 2023029063
Jan 2024026160
Feb 2024022265
Mar 2024011588
Apr 2024021972
May 2024017843
Jun 2024012236
Jul 2024019353
Aug 2024016366
Sep 2024016255
Oct 2024017452
Nov 2024022184
Dec 2024018233
Jan 2025016040
Feb 2025020039
Mar 2025016034
Apr 2025019767
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (2)
Journal of Nuclear Medicine
Vol. 61, Issue 2
February 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
FAP: The Next Billion Dollar Nuclear Theranostics Target?
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
FAP: The Next Billion Dollar Nuclear Theranostics Target?
Jeremie Calais
Journal of Nuclear Medicine Feb 2020, 61 (2) 163-165; DOI: 10.2967/jnumed.119.241232

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
FAP: The Next Billion Dollar Nuclear Theranostics Target?
Jeremie Calais
Journal of Nuclear Medicine Feb 2020, 61 (2) 163-165; DOI: 10.2967/jnumed.119.241232
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • WHY IS FAP A PROMISING TARGET?
    • WHAT ARE CAFS?
    • WHY IS FAP-TARGETED THERAPY ATTRACTIVE?
    • WHY IS FAP-TARGETED IMAGING ATTRACTIVE?
    • FAP-TARGETED RADIOPHARMACEUTICALS
    • IS THE INDUSTRY INVESTING IN FAP-TARGETED NUCLEAR THERANOSTICS?
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library
  • Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-{alpha} (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors
  • One Hundred Years of the Tracer Principle
  • A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake
  • Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging
  • Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody
  • Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
  • A novel dimeric FAP-targeting small molecule-radio conjugate with high and prolonged tumour uptake
  • The Annual Journal Impact Factor Saga
  • An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications
  • Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography
  • The Future of Nuclear Medicine Depends on the Quality of Its Research: Researchers at the University of Heidelberg Receive the Award for Best Article of the Year
  • Google Scholar

More in this TOC Section

  • RECIP 1.0: A Roadmap for Clinical Implementation
  • Diagnostic Radiopharmaceutical Trial Design: Is It Time to Change Nomenclature?
  • From Stabilization to Depletion: Molecular Imaging to Measure Therapeutic Response in ATTR-CA
Show more Hot Topics

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire